Infographic: How Young Adult Cancer Survivors Are Hit Hard by Treatment Costs

Interclass biologic switching can improve outcomes, but it also increases infection rates.

Zongertinib gains FDA approval for treating HER2-mutated non–small cell lung cancer (NSCLC), offering hope with fewer side effects and promising response rates in patients.

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

The FDA approved multiple groundbreaking treatments in July, enhancing options across patient populations.

Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.